Regenerative medicine company, Mesoblast Limited (ASX:MSB;USOTC:MBLTY), announced today that its adult stem cell technology platform has been awarded the 2008 Frost & Sullivan United States Stem Cell Market Technology Innovation of the Year.
HELICON GROUP LIMITED (ASX:HCG) announced today that it has implemented a restructuring and cost reduction program in response to the ongoing delays by the Chinese regulatory authority, the State Food and Drug Administration (SFDA), to grant regulatory approvals across the board and an anticipated slow down in economic activity in China.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced today that the thirteenth patient enrolled in the ongoing Phase 2 clinical trial for congestive heart failure had been safely implanted with the proprietary adult stem cells during a live case at the American Heart Association's annual conference, currently underway in New Orleans.
Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), is featured today at the 2008 UBS Australian Healthcare Conference underway in Sydney as one of three leading emerging companies in the biotechnology space.
Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent focused on producing Double-Stranded Nucleic Acid constructs for therapeutic and related applications of RNA interference (RNAi) had been granted in Singapore.
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the commencement of a Phase I/II clinical trial in the United States using the patented allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) in up to 30 patients with haematologic malignancies undergoing bone marrow transplantation.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.
